title: Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study.
abstract: OBJECTIVE
  To compare the efficacy, safety, and overall risk-benefit profile of enoxaparin and unfractionated heparin (UFH) prophylaxis of venous thromboembolic complications in patients with acute ischaemic stroke.
  
  
  METHODS
  Patients with ischaemic stroke resulting in lower-limb paralysis lasting for at least 24 h and necessitating bedrest, were randomized within 48 h of the onset of stroke, and treated with enoxaparin (40 mg subcutaneously once daily) or UFH (5000 IU subcutaneously thrice daily) for 10 +/- 2 days. Main outcome measures were deep-vein thrombosis, pulmonary embolism (PE), death from any cause, intracranial haemorrhage including haemorrhagic infarction, or any other major bleeding.
  
  
  RESULTS
  Outcome events occurred within 3 months of stroke in 40/106 patients treated with enoxaparin (37.7%) and 52/106 patients treated with UFH (49.1%, P=0.127). Fewer patients treated with enoxaparin (14, 13.2%) than with UFH (20, 18.9%) had evidence of haemorrhagic transformation of ischaemic stroke.
  
  
  CONCLUSIONS
  Enoxaparin administered subcutaneously once daily was as safe and effective as subcutaneous UFH given thrice daily in the prevention of thromboembolic events in patients with lower limb paralysis caused by acute ischaemic stroke.
authors.affiliation: Department of Neutology, Oulu University Hospital Oulu, Finland. matti.hillbom@oulu.fi
authors.forename: M
authors.initials: M
authors.lastname: Hillbom
authors.forename: T
authors.initials: T
authors.lastname: Erilä
authors.forename: K
authors.initials: K
authors.lastname: Sotaniemi
authors.forename: T
authors.initials: T
authors.lastname: Tatlisumak
authors.forename: S
authors.initials: S
authors.lastname: Sarna
authors.forename: M
authors.initials: M
authors.lastname: Kaste
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000410:Alanine Transaminase / Q000097:blood; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D001219:Aspartate Aminotransferases / Q000097:blood; D002545:Brain Ischemia / Q000150:complications / Q000188:drug therapy / Q000401:mortality; D004311:Double-Blind Method; D017984:Enoxaparin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006454:Hemoglobins; D006470:Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D020521:Stroke / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000188:drug therapy / Q000401:mortality / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D017984:Enoxaparin; D006454:Hemoglobins; D006493:Heparin; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase